16 active not recruiting, 15 completed, 8 terminated, 8 withdrawn. 35 Phase 2, 31 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow tazemetostat: new trials by email Literature Review of tazemetostat trials Research Report on tazemetostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer SHR-4394, Rezvilutamide, HRS-5041 Tablets - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2026-04-08 | 2026-04-21 |
| Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma Tazemetostat, Linperlisib, Golidocitinib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 48 | 2025-10-01 | 2025-10-06 |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Tazverik (Tazemetostat) - Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Withdrawn | Epizyme, Inc. | 2025-09-02 | 2026-01-30 | |
| Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Suspended | City of Hope Medical Center | 33 | 2025-03-11 | 2026-01-21 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Biospecimen Collection, Computed Tomography, Echocardiography - B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Northwestern University | 11 | 2024-09-30 | 2026-09-14 |
| Study of Tazemetostat in Lymphoid Malignancies Tazemetostat - T-cell Lymphoma | Phase 1 | Terminated | University of Alabama at Birmingham | 6 | 2024-09-05 | 2026-04-17 |
| A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer Tazverik - Prostate Cancer | Early Phase 1 | Withdrawn | Edwin Posadas, MD | 2023-12-01 | 2023-09-22 | |
| Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma Mosunetuzumab, Tazemetostat Pill - Follicular Lymphoma | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 23 | 2023-11-01 | 2026-04-02 |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Tazemetostat Pill - Follicular Lymphoma, B-Cell Lymphoma | Phase 1 | Active not recruiting | Weill Medical College of Cornell University | 15 | 2023-10-04 | 2026-06-17 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2025-10-20 |
| Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma Docetaxel, Cis Platinum, 5-FU - Sinonasal Carcinoma | Phase 2 | Not yet recruiting | Dr. Victor H.F. Lee | 30 | 2023-09-01 | 2023-02-28 |
| Tazemetostat and Palbociclib With CPX-351for R/R AML Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Thomas Jefferson University | 24 | 2023-08-28 | 2026-03-12 |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Tazemetostat, Nivolumab, Ipilimumab - Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors | Phase 1 / Phase 2 | Active not recruiting | Susan Chi, MD | 49 | 2023-08-10 | 2026-04-13 |
| Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma Venetoclax, Tazemetostat - Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 1 | Terminated | Weill Medical College of Cornell University | 3 | 2023-06-07 | 2026-04-02 |
| Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma Tazemetostat, Ublituximab, Umbralisib - Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2023-05-01 | 2023-05-31 | |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma tazemetostat, HMPL-689 - Relapsed/Refractory Lymphoma | Phase 2 | Completed | Hutchmed | 61 | 2023-02-13 | 2025-01-22 |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Bendamustine, Rituximab, Tazemetostat - Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Vaishalee Kenkre | 42 | 2023-01-26 | 2026-02-17 |
| Zandelisib + Tazemetostat in R/R Follicular Lymphoma TAZEMETOSTAT, Zandelisib - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 1 / Phase 2 | Withdrawn | Jacob Soumerai, MD | 2023-01-01 | 2023-07-07 |
Showing 20 of 57. Sign in to see all of them.
Lymphoma, Follicular (18) · Lymphoma, Large B-Cell, Diffuse (9) · Sarcoma (9) · Lymphoma, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Rhabdoid Tumor (6) · Lymphoma (5) · Prostatic Neoplasms (5) · Sarcoma, Synovial (5) · Lymphoma, Mantle-Cell (3) · Mesothelioma (3) · Recurrence (3) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Glioma (2)
Epizyme, Inc. (17) · National Cancer Institute (NCI) (8) · Eisai Co., Ltd. (3) · Weill Medical College of Cornell University (3) · City of Hope Medical Center (2) · Hutchmed (2) · Bristol-Myers Squibb (1) · Dana-Farber Cancer Institute (1) · Dr. Victor H.F. Lee (1) · Edwin Posadas, MD (1) · Eric Jacobsen, MD (1) · Hoffmann-La Roche (1) · Institut Bergonié (1) · Jacob Soumerai, MD (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
United States (39) · France (10) · United Kingdom (10) · Canada (9) · Australia (6) · Belgium (6) · Germany (5) · Italy (5) · China (4) · Poland (4) · Spain (4) · Taiwan (4) · Japan (3) · Puerto Rico (2) · Ukraine (2)
Jennifer E Amengual (2) · Anish Thomas (1) · Atish Choudhury, MD PhD (1) · Bin Yang (1) · Caitlin K Gribbin, M.D. (1) · Ciprian P Gheorghe, MD, PhD (1) · Daniel J Renouf (1) · Donald W Parsons (1) · Douglas Adkins, M.D. (1) · Edwin Posadas, MD FACP (1) · Eric Jacobsen, MD (1)
PMID 33035459, PMID 40896460, PMID 29650362, PMID 32122924, PMID 33035457, PMID 33591402, PMID 35031227, PMID 35151584, PMID 35353553, PMID 35588752, PMID 37981564, PMID 38501690, PMID 39179948, PMID 39563886, PMID 41166674, PMID 42686334
2019 (5), 2015 (3), 2023 (3), P30CA033572 (2), P30CA060553 (2), U10CA180886 (2), UM1CA186689 (2), 2014 (1), 2016 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186704 (1)